Biohaven, Sosei Heptares ink deal on small-molecule CGRP antagonists
Category : #Health  By- Puja More  Date: 2020-12-03
  • share
  • Twitter
  • Facebook
  • LinkedIn
Biohaven, Sosei Heptares ink deal on small-molecule CGRP antagonists

Biohaven Pharmaceutical Holding Company and Sosei Group Corporation have signed a collaboration and licensing agreement under which the former will have the exclusive global rights for developing, manufacturing and commercializing a novel, small-molecule CGRP receptor antagonist portfolio discovered by Sosei Heptares.

The portfolio has been discovered by Sosei Heptares for treating CGRP-mediated disorders. It comprises of HTL0022562, the lead candidate advanced through preclinical development where it showed promising and differentiated properties for possible investigation in human trials.

For this licensing deal, Sosei Heptares is bound to receive US$10 million in upfront payment in cash consideration and common shares of Biohaven, research funding and is further eligible to get additional milestone, regulatory and development payments of nearly US$370 million. Also, it will be eligible for receiving tiered royalties on the net sales of products developed from this partnership.

A commercial-stage biopharma company, Biohaven boasts a portfolio of novel, best-in-class therapies for enhancing the lives of patients suffering from debilitating neuropsychiatric and neurological disorders. The firm’s neuroinnovation portfolio is inclusive of NURTEC™ ODT (rimegepant), an FDA-approved treatment for migraine as well as a broad range of late-product candidates across distinct mechanistic platforms.

These platforms are glutamate modulation for obsessive-compulsive disorder, spinocerebellar ataxia and Alzheimer's disease; CGRP receptor antagonism aimed at acute and preventive treatment of migraine and myeloperoxidase (MPO) inhibition developed for amyotrophic lateral sclerosis and multiple system atrophy.

Sosei Heptares is a global biopharmaceutical  group seeking the discovery and early development of new medicines that originate from its proprietary technology GPCR-targeted StaR® and structure-based drug design platform capabilities. The company is advancing a broad portfolio of innovative medicines for several therapeutic areas, like immunology, gastroenterology, neurology and inflammatory diseases.

 

Source Credits: https://www.prnewswire.com/news-releases/sosei-heptares-and-biohaven-enter-global-collaboration-and-license-agreement-to-advance-novel-small-molecule-cgrp-antagonist-portfolio-301182244.html

 

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Puja More    

Puja More

Puja More holds a graduate degree in Computer Science from the University of Pune. Nurturing her passion of playing with words however, Puja undertook content writing as a career path and boasts of rich experience in content production, copywriting, and digital market...

Read More

Most Read

Biohaven, Sosei Heptares ink deal on small-molecule CGRP antagonists
Biohaven, Sosei Heptares ink deal on small-molecule CGRP antagonists
By- Puja More  Date: 2020-12-03

Biohaven Pharmaceutical Holding Company and Sosei Group Corporation have signed a collaboration and licensing agreement under which the form...

Cerus receives FDA nod for INTERCEPT Blood System for Cryoprecipitation
Cerus receives FDA nod for INTERCEPT Blood System for Cryoprecipitation
By- Madhura Dethe  Date: 2020-12-02

Adding to yet other initiatives and accomplishments in the medical fraternity, a California-based pathogen-protected blood component develop...

Nigeria set to commence installation of 5Mn solar home power systems
Nigeria set to commence installation of 5Mn solar home power systems
By- Puja More  Date: 2020-12-01

The first phase of installation is expected to be commenced in December 2020 nationwide. The Federal Government of Nigeria has recently sta...

Ascentage partners with U-M to attain license for a MDM2 degrader
Ascentage partners with U-M to attain license for a MDM2 degrader
By- Puja More  Date: 2020-11-30

Acquisitions, collaborations, and mergers have become a common practice in the medical and biotechnology sector in recent years. Speaking of...

Our Conrtributor

Apple launches ‘AirPods Max’, its first over-ear headphones at $550

Apple launches ‘AirPods Max’, its first over-ear headphones at $550

By- Puja More

Technology giant- Apple Inc. has recently unveiled the ‘AirPods Max’, active noise-cance...

Zydus receives DGCI approval for Phase-1 clinical trial of ZYIL1

Zydus receives DGCI approval for Phase-1 clinical trial of ZYIL1

By- Puja More

ZYIL1 stands out to be a novel oral small molecule NLRP3 inhibitor candidate which is expected to be...

Gupshup to better business communications, launches GIP for the same

Gupshup to better business communications, launches GIP for the same

By- Puja More

Messaging services company, Gupshup has reportedly launched an all-new IP-based messaging channel wi...